- Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis A phase 2 study2014 | First Faculty of Medicine
- Current application of ritusimab in pharmacotherapy2015 | Publication without faculty affiliation
- Rituximab and its indications2019 | Publication without faculty affiliation
- MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial2020 | Faculty of Medicine in Hradec Králové